Dear Investors,
I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance.
One month following cataract surgery and implantation of the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”), their vision has improved dramatically to 20/40 or better, an extraordinary outcome at this early stage.
It’s important to note that patients must continue to heal and adapt after cataract surgery, and best vision typically develops over three to six months. The fact that our participants are seeing this level of improvement so soon after surgery is remarkable in its speed, while still aligning with the expected course of visual recovery.
These outcomes reinforce the safety, performance, and promise of the Ocumetics Lens. They demonstrate that our technology is behaving exactly as designed, offering patients the potential for clear, natural vision across all distances.
We invite you to read the October 8th press release for details, but in summary:
- The safety profile remains excellent.
- Surgical handling and implantation have been both smooth and reproducible.
- Patients with previously poor vision are now experiencing clear, functional sight and improvement is expected to continue.
This is tremendous news for Ocumetics, for our partners, and most importantly for patients worldwide who dream of life without glasses or contacts. We are building momentum, and I am more confident than ever that Ocumetics is redefining the future of vision.
Warm regards,
Dean Burns
President & CEO
Ocumetics Technology Corp.
Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including: First-in-human study timing Remaining steps to first-in-human study Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the
Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide. It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning
Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:1. Development Update on the Ocumetics IOL2. Remaining steps to first-in-human study3. Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in
Dear Stakeholders, I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials. As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In
